- Home
- AEMD vs LIXT Comparison
AEMD vs LIXT Comparison
Compare AEMD & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- LIXT
- Stock Information
- Founded
- AEMD 1984
- LIXT 2005
- Country
- AEMD United States
- LIXT United States
- Employees
- AEMD N/A
- LIXT N/A
- Industry
- AEMD Medical/Dental Instruments
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- LIXT Health Care
- Exchange
- AEMD Nasdaq
- LIXT Nasdaq
- Market Cap
- AEMD 5.0M
- LIXT 4.1M
- IPO Year
- AEMD N/A
- LIXT N/A
- Fundamental
- Price
- AEMD $0.58
- LIXT $2.02
- Analyst Decision
- AEMD Strong Buy
- LIXT
- Analyst Count
- AEMD 1
- LIXT 0
- Target Price
- AEMD $7.00
- LIXT N/A
- AVG Volume (30 Days)
- AEMD 6.6M
- LIXT 32.5K
- Earning Date
- AEMD 02-12-2025
- LIXT 11-12-2024
- Dividend Yield
- AEMD N/A
- LIXT N/A
- EPS Growth
- AEMD N/A
- LIXT N/A
- EPS
- AEMD N/A
- LIXT N/A
- Revenue
- AEMD N/A
- LIXT N/A
- Revenue This Year
- AEMD N/A
- LIXT N/A
- Revenue Next Year
- AEMD N/A
- LIXT N/A
- P/E Ratio
- AEMD N/A
- LIXT N/A
- Revenue Growth
- AEMD N/A
- LIXT N/A
- 52 Week Low
- AEMD $0.24
- LIXT $1.31
- 52 Week High
- AEMD $2.35
- LIXT $4.40
- Technical
- Relative Strength Index (RSI)
- AEMD 57.14
- LIXT 51.26
- Support Level
- AEMD $0.36
- LIXT $1.85
- Resistance Level
- AEMD $0.83
- LIXT $2.65
- Average True Range (ATR)
- AEMD 0.09
- LIXT 0.21
- MACD
- AEMD 0.02
- LIXT -0.01
- Stochastic Oscillator
- AEMD 32.84
- LIXT 21.18
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.